Q-omics provides the consensus-scored DDX53 profile across patient tissues and cancer cell-line models. DDX53 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, DDX53 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, DDX53 RNA expression shows 8,658 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, and TGCT as cancer lineages where DDX53 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX53 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX53 survival associations across molecular data types. DDX53 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX53 RNA expression–survival associations across cancer types. High DDX53 expression shows unfavorable associations in LIHC, LGG, LUSC, KICH and UCEC, but favorable associations in LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LIHC as the clearest survival context for DDX53 RNA expression.
This table summarizes DDX53 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for DDX53. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX53 shows lower tumor expression in THCA and higher tumor expression in LIHC, BRCA, LUAD and LUSC. The LIHC box plot shows higher DDX53 RNA expression in tumor versus normal tissue (log2 FC = +0.464, t-test p < 0.001).
This table shows molecular features associated with DDX53 in patient tissues and cancer cell lines. In patient samples, DDX53 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DDX53 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
